Novo Nordisk announced that Levemir is now commercially available in the United States.
“Levemir is indicated for once- or twice-daily injection for the treatment of adults and children with type 1 diabetes and adults with type 2 diabetes,” says Novo Nordisk. “The relatively flat action profile of Levemir offers patients up to 24 hours of effective blood glucose control.”
Levemir is available in vials and the Levemir FlexPen. Full prescribing information for Levemir is available from Novo Nordisk, Inc., or by logging on to www.novonordisk-us.com.